Oligodendrocyte cell death in pathogenesis of multiple sclerosis: Protection of oligodendrocytes from apoptosis by complement

Journal of Rehabilitation Research and Development

Volumn 43, Issue 1, 2006, Pages 123-132

  Cudrici, Cornelia ^a   Niculescu, Teodora ^a   Niculescu, Florin ^a   Shin, Moon L ^a   Rus, Horea ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Apoptosis; Caspases; Complement C5; Complement complex C5b 9; Experimental allergic encephalomyelitis; Fas ligand; Multiple sclerosis; Oligodendrocyte; Phosphatidylinositol 3 kinase; T lymphocyte

Indexed keywords

BIOMEDICAL ENGINEERING; CELLS; IMMUNOLOGY; NEUROLOGY;

APOPTOSIS; CASPASES; COMPLEMENT C5; COMPLEMENT COMPLEX C5B-9; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; FAS LIGAND; MULTIPLE SCLEROSIS; OLIGODENDROCYTE; PATHOGENESIS;

DISEASES;

CASPASE 11; COMPLEMENT; COMPLEMENT COMPONENT C5; COMPLEMENT COMPONENT C5B; FAS ANTIGEN; FAS LIGAND; GAMMA INTERFERON; MYELIN; TUMOR NECROSIS FACTOR ALPHA;

ALLERGIC ENCEPHALOMYELITIS; APOPTOSIS; CELL ACTIVATION; CELL DEATH; CELL LOSS; CELL PROTECTION; CENTRAL NERVOUS SYSTEM; CHRONIC DISEASE; COMPLEMENT ACTIVATION; DEMYELINATING DISEASE; HUMAN; IN VIVO STUDY; INFLAMMATION; LYMPHOCYTE ACTIVATION; MACROPHAGE ACTIVATION; MICROGLIA; MULTIPLE SCLEROSIS; MYELINATION; NERVE FIBER; NONHUMAN; OLIGODENDROGLIA; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; TARGET CELL;

ANIMALS; APOPTOSIS; CASPASES; CELL DEATH; COMPLEMENT ACTIVATION; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FAS LIGAND PROTEIN; HUMANS; MICE; MULTIPLE SCLEROSIS; NEUROPROTECTIVE AGENTS; OLIGODENDROGLIA; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 33745311758     PISSN: 07487711     EISSN: 07487711     Source Type: Journal    
DOI: 10.1682/JRRD.2004.08.0111     Document Type: Review

References (65)

1. Steinman L. Multiple sclerosis: a two-stage disease. Nat Immunol. 2001;2(9):762-64.
2. Compston A. The pathogenesis and basis for treatment in multiple sclerosis. Clin Neurol Neurosurg. 2004;106(3):246-48.
3. Lucchinetti CF, Bruck W, Noseworthy J. Multiple sclerosis: recent developments in neuropathology, pathogenesis, magnetic resonance imaging studies and treatment. Curr Opin Neurol. 2001;14(3):259-69.
4. Barnett MH, Prineas JW. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann Neurol. 2004;55(4):458-68.
5. Hemmer B, Archelos JJ, Hartung HP. New concepts in the immunopathogenesis of multiple sclerosis. Nat Rev Neurosci. 2002;3(4):291-301.
6. Vanderlugt CL, Miller SD. Epitope spreading in immunemediated diseases: implications for immunotherapy. Nat Rev Immunol. 2002;2(2):85-95.
7. Ledeen RW, Chakraborty G. Cytokines, signal transduction, and inflammatory demyelination: review and hypothesis. Neurochem Res. 1998;23(3):277-89.
8. Hellings N, Baree M, Verhoeven C, D'hooghe MB, Medaer R, Bernard CC, Raus J, Stinissen P. T-cell reactivity to multiple myelin antigens in multiple sclerosis patients and healthy controls. J Neurosci Res. 2001;63(3): 290-302.
9. Lovett-Racke AE, Trotter JL, Lauber J, Perrin PJ, June CH, Racke MK. Decreased dependence of myelin basic proteinreactive T cells on CD28-mediated costimulation in multiple sclerosis patients. A marker of activated/memory T cells. J Clin Invest. 1998;101(4):725-30. [PMID: 9466965] Erratum in: J Clin Invest. 1998;101(7):1542.
10. Tejada-Simon MV, Hong J, Rivera VM, Zhang JZ. Reactivity pattern and cytokine profile of T cells primed by myelin peptides in multiple sclerosis and healthy individuals. Eur J Immunol. 2001;31(3):907-17.
11. Ozenci V, Kouwenhoven M, Link H. Cytokines in multiple sclerosis: methodological aspects and pathogenic implications. Mult Scler. 2002;8(5):396-404.
12. Sellebjerg F, Sorensen TL. Chemokines and matrix metalloproteinase-9 in leukocyte recruitment to the central nervous system. Brain Res Bull. 2003;61(3):347-55.
13. Bar-Or A, Nuttall RK, Duddy M, Alter A, Kim HJ, Ifergan I, Pennington CJ, Bargoin P, Edwards DR, Yong VW. Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis. Brain. 2003;126(Pt 12):2738-49.
14. Babcock A, Owens T. Chemokines in experimental autoimmune encephalomyelitis and multiple sclerosis. Adv Exp Med Biol. 2003;520:120-32.
15. Lafaille JJ, Keere FV, Hsu AL, Baron JL, Haas W, Raine CS, Tonegawa S. Myelin basic protein-specific T helper 2 (Th2) cells cause experimental autoimmune encephalomyelitis in immunodeficient hosts rather than protect them from the disease. J Exp Med. 1997;186(2):307-12.
16. Cannella B, Gao YL, Brosnan C, Raine CS. IL-10 fails to abrogate experimental autoimmune encephalomyelitis. J Neurosci Res. 1996;45(6):735-46.
17. Stefferl A, Brehm U, Storch M, Lambracht-Washington D, Bourquin C, Wonigeit K, Lassmann H, Linington C. Myelin oligodendrocyte glycoprotein induces experimental autoimmune encephalomyelitis in the "resistant" Brown Norway rat: disease susceptibility is determined by MHC and MHC-linked effects on the B cell response. J Immunol. 1999;163(1):40-49.
18. Lucchinetti CF, Mandler RN, McGavern D, Bruck W, Gleich G, Ransohoff RM, Trebst C, Weinshenker B, Wingerchuk D, Parisi JE, Lassmann H. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain. 2002;125(Pt 7):1450-61.
19. Huseby ES, Liggitt D, Brabb T, Schnabel B, Ohlen C, Goverman J. A pathogenic role for myelin-specific CD8(+) T cells in a model for multiple sclerosis. J Exp Med. 2001;194(5):669-76.
20. Sun D, Whitaker JN, Huang Z, Liu D, Coleclough C, Wekerle H, Raine CS. Myelin antigen-specific CD8+ T cells are encephalitogenic and produce severe disease in C57BL/6 mice. J Immunol. 2001;166(12):7579-87.
21. Skulina C, Schmidt S, Dornmair K, Babbe H, Roers A, Rajewsky K, Wekerle H, Hohlfeld R, Goebels N. Multiple sclerosis: Brain-infiltrating CD8+ T cells persist as clonal expansions in the cerebrospinal fluid and blood. Proc Natl Acad Sci U S A. 2004;101(8):2428-33.
22. Neumann H, Medana IM, Bauer J, Lassmann H. Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases. Trends Neurosci. 2002;25(6):313-19.
23. Seil FJ. Tissue culture studies of demyelinating disease: a critical review. Ann Neurol. 1977;2(4):345-55.
24. Liu WT, Vanguri P, Shin ML. Studies on demyelination in vitro: the requirement of membrane attack components of the complement system. J Immunol. 1983;131(2):778-82.
25. Scolding NJ, Morgan BP, Houston WA, Linington C, Campbell AK, Compston DA. Vesicular removal by oligodendrocytes of membrane attack complexes formed by activated complement. Nature. 1989;339(6226):620-22.
26. Sharma K, Wang RX, Zhang LY, Yin DL, Luo XY, Solomon JC, Jiang RF, Markos K, Davidson W, Scott DW, Shi YF. Death the Fas way: regulation and pathophysiology of CD95 and its ligand. Pharmacol Ther. 2000;88(3):333-47.
27. Esposti MD. The roles of Bid. Apoptosis. 2002;7(5):433-40.
28. D'Souza SD, Bonetti B, Balasingam V, Cashman NR, Barker PA, Troutt AB, Raine CS, Antel JP. Multiple sclerosis: Fas signaling in oligodendrocyte cell death. J Exp Med. 1996;184(6):2361-70.
29. Dowling P, Husar W, Menonna J, Donnenfeld H, Cook S, Sidhu M. Cell death and birth in multiple sclerosis brain. J Neurol Sci. 1997;149(1):1-11.
30. Pouly S, Becher B, Blain M, Antel JP. Interferon-gamma modulates human oligodendrocyte susceptibility to Fas-mediated apoptosis. J Neuropathol Exp Neurol. 2000;59(4):280-86.
31. Li W, Maeda Y, Ming X, Cook S, Chapin J, Husar W, Dowling P. Apoptotic death following Fas activation in human oligodendrocyte hybrid cultures. J Neurosci Res. 2002;69(2):189-96.
32. Hisahara S, Araki T, Sugiyama F, Yagami K, Suzuki M, Abe K, Yamamura K, Miyazaki J, Momoi T, Saruta T, Bernard CC, Okano H, Miura M. Targeted expression of baculovirus p35 caspase inhibitor in oligodendrocytes protects mice against autoimmune-mediated demyelination. EMBO J. 2000;19(3):341-48.
33. Hisahara S, Yuan J, Momoi T, Okano H, Miura M. Caspase-11 mediates oligodendrocyte cell death and pathogenesis of autoimmune-mediated demyelination. J Exp Med. 2001;193(1):111-22.
34. Choi C, Benveniste EN. Fas ligand/Fas system in the brain: regulator of immune and apoptotic responses. Brain Res Brain Res Rev. 2004;44(1):65-81.
35. Sabelko-Downes KA, Cross AH, Russell JH. Dual role for Fas ligand in the initiation of and recovery from experimental allergic encephalomyelitis. J Exp Med. 1999;189(8):1195-1205.
36. Sabelko-Downes KA, Russell JH, Cross AH. Role of Fas-FasL interactions in the pathogenesis and regulation of autoimmune demyelinating disease. J Neuroimmunol. 1999;100(1-2):42-52.
37. Zhu B, Luo L, Chen Y, Paty DW, Cynader MS. Intrathecal Fas ligand infusion strengthens immunoprivilege of central nervous system and suppresses experimental autoimmune encephalomyelitis. J Immunol. 2002;169(3):1561-69.
38. Robbins DS, Shirazi Y, Drysdale BE, Lieberman A, Shin HS, Shin ML. Production of cytotoxic factor for oligodendrocytes by stimulated astrocytes. J Immunol. 1987;139(8):2593-97.
39. Selmaj KW, Raine CS. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol. 1988;23(4):339-46.
40. Louis JC, Magal E, Takayama S, Varon S. CNTF protection of oligodendrocytes against natural and tumor necrosis factor-induced death. Science. 1993;259(5095):689-92.
41. Hisahara S, Shoji S, Okano H, Miura M. ICE/CED-3 family executes oligodendrocyte apoptosis by tumor necrosis factor. J Neurochem. 1997;69(1):10-20.
42. Tchelingerian JL, Monge M, Le Saux F, Zalc B, Jacque C. Differential oligodendroglial expression of the tumor necrosis factor receptors in vivo and in vitro. J Neurochem. 1995;65(5):2377-80.
43. Lieberman AP, Pitha PM, Shin HS, Shin ML. Production of tumor necrosis factor and other cytokines by astrocytes stimulated with lipopolysaccharide or a neurotropic virus. Proc Natl Acad Sci U S A. 1989;86(16):6348-52.
44. Chung IY, Benveniste EN. Tumor necrosis factor-alpha production by astrocytes. Induction by lipopolysaccharide, IFN-gamma, and IL-1 beta. J Immunol. 1990;144(8):2999-3007.
45. Merrill JE, Ignarro LJ, Sherman MP, Melinek J, Lane TE. Microglial cell cytotoxicity of oligodendrocytes is mediated through nitric oxide. J Immunol. 1993;151(4):2132-41.
46. Sharief MK, Hentges R. Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis. N Engl J Med. 1991;325(7):467-72.
47. Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Sandberg G, Crayton H, Richert JR, Siegal JN. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum. 2001;44(12):2862-69.
48. Panitch HS, Hirsch RL, Schindler J, Johnson KP. Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system. Neurology. 1987;37(7):1097-1102.
49. Andrews T, Zhang P, Bhat NR. TNF potentiates IFN-induced cell death in oligodendrocyte progenitors. J Neurosci Res. 1998;54(5):574-83.
50. Ozawa K, Suchanek G, Breitschopf H, Bruck W, Budka H, Jellinger K, Lassmann H. Patterns of oligodendroglia pathology in multiple sclerosis. Brain. 1994;117(Pt 6):1311-22.
51. Wolswijk G. Oligodendrocyte survival, loss and birth in lesions of chronic-stage multiple sclerosis. Brain. 2000;123(Pt 1):105-15.
52. Bonetti B, Raine CS. Multiple sclerosis: oligodendrocytes display cell death-related molecules in situ but do not undergo apoptosis. Ann Neurol. 1997;42(1):74-84.
53. Ming X, Li W, Maeda Y, Blumberg B, Raval S, Cook SD, Dowling PC. Caspase-1 expression in multiple sclerosis plaques and cultured glial cells. J Neurol Sci. 2002;197(1-2):9-18.
54. Furlan R, Martino G, Galbiati F, Poliani PL, Smiroldo S, Bergami A, Desina G, Comi G, Flavell R, Su MS, Adorini L. Caspase-1 regulates the inflammatory process leading to autoimmune demyelination. J Immunol. 1999;163(5):2403-9.
55. Rus H, Niculescu F, Shin ML. Sublytic complement attack induces cell cycle in oligodendrocytes. J Immunol. 1996;156(12):4892-4900.
56. Soane L, Rus H, Niculescu F, Shin ML. Inhibition of oligodendrocyte apoptosis by sublytic C5b-9 is associated with enhanced synthesis of bcl-2 and mediated by inhibition of caspase-3 activation. J Immunol. 1999;163(11):6132-38.
57. Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell. 1996;87(4):619-28.
58. Soane L, Cho HJ, Niculescu F, Rus H, Shin ML. C5b-9 terminal complement complex protects oligodendrocytes from death by regulating Bad through phosphatidylinositol 3-kinase/Akt pathway. J Immunol. 2001;167(4):2305-11.
59. Linington C, Morgan BP, Scolding NJ, Wilkins P, Piddlesden S, Compston DA. The role of complement in the pathogenesis of experimental allergic encephalomyelitis. Brain. 1989;112(Pt 4):895-911.
60. Piddlesden SJ, Storch MK, Hibbs M, Freeman AM, Lassmann H, Morgan BP. Soluble recombinant complement receptor 1 inhibits inflammation and demyelination in antibody-mediated demyelinating experimental allergic encephalomyelitis. J Immunol. 1994;152(11):5477-84.
61. Nataf S, Carroll SL, Wetsel RA, Szalai AJ, Barnum SR. Attenuation of experimental autoimmune demyelination in complement-deficient mice. J Immunol. 2000;165(10):5867-73.
62. Mead RJ, Singhrao SK, Neal JW, Lassmann H, Morgan BP. The membrane attack complex of complement causes severe demyelination associated with acute axonal injury. J Immunol. 2002;168(1):458-65.
63. Tran GT, Hodgkinson SJ, Carter N, Killingsworth M, Spicer ST, Hall BM. Attenuation of experimental allergic encephalomyelitis in complement component 6-deficient rats is associated with reduced complement C9 deposition, P-selectin expression, and cellular infiltrate in spinal cords. J Immunol. 2002;168(9):4293-4300.
64. Weerth SH, Rus H, Shin ML, Raine CS. Complement C5 in experimental autoimmune encephalomyelitis (EAE) facilitates remyelination and prevents gliosis. Am J Pathol. 2003;163(3):1069-80.
65. Niculescu T, Weerth S, Niculescu F, Cudrici C, Rus V, Raine CS, Shin ML, Rus H. Effects of complement C5 on apoptosis in experimental autoimmune encephalomyelitis. J Immunol. 2004;172(9):5702-6.